Sugi Predict

Sugi Predict / Compounds / SCHEMBL274197

SCHEMBL274197

SCHEMBL274197

CC1(C)OB(c2ccc3c(c2)CNC3=O)OC1(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 2/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ FLT3 P36888 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ CLK4 Q9HAZ1 1/20 0.43
▸ GRM5 P41594 4/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ PRF1 P14222 6/20 0.40
▸ LPL P06858 3/20 0.38
▸ LIPG Q9Y5X9 3/20 0.38
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.36
▸ TBK1 Q9UHD2 1/20 0.36
▸ BRAF P15056 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392410 0.88 CLK4 (0.44) ROCK1NTRK1FLT3GSK3BCLK4
SCHEMBL29609304 0.88 CLK4 (0.44) ROCK1NTRK1FLT3GSK3BCLK4
SCHEMBL1636716 0.86 PARP10 (0.54) GRM5
SCHEMBL30720809 0.86 PARP10 (0.54) GRM5
SCHEMBL12078239 0.83 PARP10 (0.38) ROCK1GRM5CA12CA9LPL
SCHEMBL29964464 0.83 PARP11 (0.44) GSK3BGRM5LPLLIPG
SCHEMBL12077902 0.83 PARP11 (0.44) GSK3BGRM5LPLLIPG
SCHEMBL328270 0.81 DAPK3 (0.38) ROCK1DAPK3NTRK1PIM1FLT3
SCHEMBL394338 0.79 PRMT5 (0.37) ROCK1CA12CA9LPLLIPG
SCHEMBL25431012 0.78 LIPG (0.41) ROCK1CA12CA9LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024016826-A1 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF 杭州市第七人民医院 2024-01-25 — — WO claimed
WO-2026090104-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-20260109684-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF NEW YORK UNIVERSITY (US) 2026-04-23 — — US disclosed
EP-4719385-A2 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS University of Vermont and State Agricultural College (US) 2026-04-08 — — EP disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 — — US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-1709022-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-10-11 — — EP disclosed
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 — — US disclosed
US-6995155-B2 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2006-02-07 — — US disclosed
WO-2005073205-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-08-11 — — WO disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 — — US disclosed
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2004-02-05 — — US disclosed
EP-1326849-A1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE Merck Sharp & Dohme Limited (GB) 2003-07-16 — — EP disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 — — EP disclosed
WO-2002030912-A1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE MERCK SHARP & DOHME LIMITED (GB) 2002-04-18 — — WO disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 ROCK1 3449/4885DAPK3 1656/4885NTRK1 2908/4885
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP ROCK1 3947/4885DAPK3 1137/4885NTRK1 2362/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 ROCK1 2492/4885DAPK3 443/4885NTRK1 2785/4885
US-20260109684-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF AGER, GLP1R, HMGB1 ROCK1 176/4885DAPK3 1214/4885NTRK1 645/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 ROCK1 620/4885DAPK3 3216/4885NTRK1 3726/4885
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase BACE1, BACE2, PSEN1 ROCK1 4429/4885DAPK3 1646/4885NTRK1 3121/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 ROCK1 1150/4885DAPK3 4667/4885NTRK1 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.